Cystatin B and Clusterin Biomarkers for Progressive CKD Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting chronic kidney disease (CKD) in mammals, such as canines and felines, are inadequate for differentiating stable CKD from progressive CKD in a timely manner, relying on invasive procedures like biopsy and insensitive markers like serum creatinine and SDMA, which require multiple visits and long observation periods.
Innovation Solution
The use of Cystatin B and clusterin polypeptides as biomarkers, determined at a single time point, to differentiate stable from progressive CKD by comparing their levels to a control sample, facilitating early detection and intervention.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If serum creatinine and SDMA are used for CKD detection, then the method is simple and widely available, but the sensitivity is poor and cannot detect early or mild CKD
Solution Approach 1:
The patent changes the detection parameter from traditional serum creatinine and SDMA to Cystatin B and clusterin polypeptides. These new markers provide superior sensitivity for early CKD detection while maintaining practical applicability through standardized immunoassay methods.
Solution Approach 2:
The patent replaces the biochemical measurement approach (creatinine/SDMA) with a polypeptide-based immunodetection system. This substitution enables earlier and more sensitive detection of kidney injury through antibody-based assays that can identify disease before traditional markers show abnormalities.
2Measurement precision
If biopsy is used for CKD detection, then the diagnostic accuracy is high, but the method is invasive and limited for early screening
Solution Approach 1:
The patent introduces Cystatin B and clusterin polypeptides as intermediary biomarkers that reflect kidney injury without requiring direct tissue examination. These mediators provide biopsy-level diagnostic information through non-invasive blood or urine samples, enabling widespread screening while maintaining high diagnostic accuracy.
Solution Approach 2:
The patent extracts the diagnostic information function from the invasive biopsy procedure and transfers it to circulating polypeptide markers. This extraction allows the same diagnostic capability to be obtained through simple blood draws or urine collection, making early screening accessible and practical.
3Loss of information
If traditional CKD detection methods are used, then the current standard of care is maintained, but the ability to differentiate stable from progressive CKD is insufficient
Solution Approach 1:
The patent segments the CKD patient population into stable and progressive subgroups using Cystatin B and clusterin levels as discriminators. This segmentation enables tailored treatment approaches and improves clinical management by identifying which patients require more aggressive intervention based on their progression risk.
Solution Approach 2:
The patent establishes a feedback mechanism where Cystatin B and clusterin levels provide real-time information about kidney injury progression. This feedback allows clinicians to monitor disease course and adjust treatments dynamically, improving outcomes by responding to actual disease state rather than relying on static traditional markers.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Cystatin B and clusterin polypeptides provide a reliable and timely indication of CKD progression, allowing for early intervention and improved patient management by distinguishing between stable and progressive forms of the disease.
Implementation Method 1
determining the amount of Cystatin B polypeptides, clusterin polypeptides, or both, in a sample from the subject at a single time point
Data Source
AI summary
The disclosure provides methods and compositions for detection and differentiation of stable CKD and progressive CKD in mammals.